03:05:14 EDT Mon 24 Jun 2024
Enter Symbol
or Name

Login ID:
Resverlogix Corp
Symbol RVX
Shares Issued 272,371,322
Close 2024-02-21 C$ 0.065
Market Cap C$ 17,704,136
Recent Sedar Documents

Resverlogix director Lu resigns

2024-02-21 19:09 ET - News Release

Mr. Donald McCaffrey reports


Resverlogix Corp.'s Shawn Lu has stepped down from the board of directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's president and chief executive officer.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. The company aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities and post-COVID-19 conditions.

Resverlogix has partnered with Eversana, the pioneer of next-generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post-COVID-19 conditions and pulmonary arterial hypertension in Canada and the United States.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.